KatarÃ-na Sebekova

List of Publications by Year
in descending order

142	3,261	147801	189892
papers	citations	31 h-index	50 g-index

150	150	150	4187
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bone mineral density and oxidative stress in adolescent girls with anorexia nervosa. European Journal of Pediatrics, 2022, 181, 311-321.	2.7	7
2	Long-Term Consumption of a Sugar-Sweetened Soft Drink in Combination with a Western-Type Diet Is Associated with Morphological and Molecular Changes of Taste Markers Independent of Body Weight Development in Mice. Nutrients, 2022, 14, 594.	4.1	3
3	Lean insulin-resistant young adults display increased cardiometabolic risk: A retrospective cross-sectional study. Diabetes Research and Clinical Practice, 2022, 185, 109217.	2.8	4
4	Elevated blood pressure-associated cardiometabolic risk factors and biomarkers in 16â€“23 years old students with or without metabolic abnormalities. Journal of Human Hypertension, 2021, 35, 37-48.	2.2	3
5	Neurodevelopmental testing of mice in the neonatal period does not affect their locomotor activity, depressive- and anxiety-like behaviour in adolescence. Behavioural Brain Research, 2021, 404, 113170.	2.2	0
6	Oxidative status in plasma, urine and saliva of girls with anorexia nervosa and healthy controls: a cross-sectional study. Journal of Eating Disorders, 2021, 9, 54.	2.7	6
7	Circulating extracellular DNA is in association with continuous metabolic syndrome score in healthy adolescents. Physiological Genomics, 2021, 53, 309-318.	2.3	6
8	A considerable proportion of metabolic syndromeâ€“free adults from Bratislava Region, Slovakia, display an increased cardiometabolic burden. Canadian Journal of Physiology and Pharmacology, 2021, 99, 974-982.	1.4	0
9	Creatinine-Based Formulae Poorly Match in the Classification of Hypofiltration or Hyperfiltration in a General Population of Adolescents: A Retrospective Analysis of a Cross-Sectional Study. Frontiers in Pediatrics, 2021, 9, 719997.	1.9	2
10	Dynamics of salivary markers of kidney functions in acute and chronic kidney diseases. Scientific Reports, 2020, 10, 21260.	3.3	12
11	Asymptomatic Hyperuricemia Associates with Cardiometabolic Risk Indicators in Overweight/Obese but Not in Lean Adolescents . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 3977-3992.	2.4	4
12	Sex Differences in Association of Elevated Blood Pressure with Variables Characterizing Cardiometabolic Risk in Young Subjects with or Without Metabolic Abnormalities. International Journal of Environmental Research and Public Health, 2020, 17, 3612.	2.6	4
13	Maternal Consumption of a Diet Rich in Maillard Reaction Products Accelerates Neurodevelopment in F1 and Sex-Dependently Affects Behavioral Phenotype in F2 Rat Offspring. Foods, 2019, 8, 168.	4.3	9
14	Estimation of the proportion of metabolic syndrome-free subjects on high cardiometabolic risk using two continuous cardiometabolic risk scores: a cross-sectional study in 16- to 20-year-old individuals. European Journal of Pediatrics, 2019, 178, 1243-1253.	2.7	5
15	Glycated proteins in nutrition: Friend or foe?. Experimental Gerontology, 2019, 117, 76-90.	2.8	16
16	Metabolic and Renal Effects of Dietary Advanced Glycation end Products in Pregnant Rats â€“ A Pilot Study. Physiological Research, 2019, 68, 467-479.	0.9	6
17	Oxidative stress in the brain caused by acute kidney injury. Metabolic Brain Disease, 2018, 33, 961-967.	2.9	21
18	Prevalence of overweight/obesity among 7-year-old childrenâ€”WHO Childhood Obesity Surveillance Initiative in Slovakia, trends and differences between selected European countries. European Journal of Pediatrics, 2018, 177, 945-953.	2.7	7

#	Article	IF	Citations
19	Plasma markers of oxidative status were associated with increasing continuous cardiometabolic risk scores in healthy students aged 16â€“20 years without central obesity. Acta Paediatrica, International Journal of Paediatrics, 2018, 107, 2137-2145.	1.5	2
20	Gender Differences in Cardiometabolic Risk Factors in Metabolically Healthy Normal Weight Adults with Central Obesity. Experimental and Clinical Endocrinology and Diabetes, 2018, 126, 309-315.	1.2	1
21	Continuous metabolic syndrome score (siMS) enables quantification of severity of cardiometabolic affliction in individuals not presenting with metabolic syndrome. Bratislava Medical Journal, 2018, 119, 675-678.	0.8	7
22	The effects of a maternal advanced glycation end product-rich diet on somatic features, reflex ontogeny and metabolic parameters of offspring mice. Food and Function, 2018, 9, 3432-3446.	4.6	17
23	Salivary creatinine and urea are higher in an experimental model of acute but not chronic renal disease. PLoS ONE, 2018, 13, e0200391.	2.5	14
24	Gender-associated differences in the prevalence of central obesity using waist circumference and waist-to-height ratio, and that of general obesity, in Slovak adults. Central European Journal of Public Health, 2018, 26, 228-233.	1.1	6
25	Markers of Oxidative Stress and Antioxidant Status in the Plasma, Urine and Saliva of Healthy Mice. Physiological Research, 2018, 67, 921-934.	0.9	30
26	Variables associated with unplanned general adult ICU admission in hospitalised patients: protocol for a systematic review. Systematic Reviews, 2017, 6, 67.	5.3	4
27	Association between metabolically healthy central obesity in women and levels of soluble receptor for advanced glycation end products, soluble vascular adhesion protein-1, and activity of semicarbazide-sensitive amine oxidase. Croatian Medical Journal, 2017, 58, 106-116.	0.7	14
28	Improvement in asymmetric dimethylarginine and oxidative stress in patients with limb salvage after autologous mononuclear stem cell application for critical limb ischemia. Stem Cell Research and Therapy, 2017, 8, 165.	5.5	6
29	Vitamin D status in apparently healthy medication-free Slovaks: Association to blood pressure, body mass index, self-reported smoking status and physical activity. Bratislava Medical Journal, 2017, 117, 702-709.	0.8	9
30	Ethnicity and skin autofluorescence-based risk-engines for cardiovascular disease and diabetes mellitus. PLoS ONE, 2017, 12, e0185175.	2.5	13
31	Dietary AGEs May Have Different Effects in People with Vegetarian versus Omnivorous Eating Patterns. , 2017, , 225-238.		0
32	Correlation among soluble receptors for advanced glycation end-products, soluble vascular adhesion protein-1/semicarbazide-sensitive amine oxidase (sVAP-1) and cardiometabolic risk markers in apparently healthy adolescents: a cross-sectional study. Glycoconjugate Journal, 2016, 33, 599-606.	2.7	12
33	Salivary markers of kidney function â€" Potentials and limitations. Clinica Chimica Acta, 2016, 453, 28-37.	1.1	36
34	Serum carboxymethyl-lysine, a dominant advanced glycation end product, is increased in women with gestational diabetes mellitus. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2016, 160, 70-75.	0.6	22
35	Interplay of Vitamin D, Erythropoiesis, and the Renin-Angiotensin System. BioMed Research International, 2015, 2015, 1-11.	1.9	77
36	Extraskeletal Functions of Vitamin D. BioMed Research International, 2015, 2015, 1-2.	1.9	11

#	Article	IF	Citations
37	Is Vitamin D Deficiency Related to Accumulation of Advanced Glycation End Products, Markers of Inflammation, and Oxidative Stress in Diabetic Subjects?. BioMed Research International, 2015, 2015, 1-15.	1.9	16
38	25-Hydroxyvitamin D and Advanced Glycation Endproducts in Healthy and Hypertensive Subjects: Are There Interactions?. , 2015, 25, 209-216.		11
39	Prenatal dietary load of Maillard reaction products combined with postnatal Coca-Cola drinking affects metabolic status of female Wistar rats. Croatian Medical Journal, 2015, 56, 94-103.	0.7	9
40	Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST. Nanotoxicology, 2015, 9, 118-132.	3.0	75
41	Chronic renal insufficiency does not induce behavioral and cognitive alteration in rats. Physiology and Behavior, 2015, 138, 133-140.	2.1	18
42	Presence of Cardiometabolic Risk Factors Is Not Associated with Microalbuminuria in 14-to-20-Years Old Slovak Adolescents: A Cross-Sectional, Population Study. PLoS ONE, 2015, 10, e0129311.	2.5	16
43	Vitamin D Levels Decline with Rising Number of Cardiometabolic Risk Factors in Healthy Adults: Association with Adipokines, Inflammation, Oxidative Stress and Advanced Glycation Markers. PLoS ONE, 2015, 10, e0131753.	2.5	19
44	Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population. Diabetic Medicine, 2014, 31, 581-585.	2.3	24
45	Total plasma NÎµ-(carboxymethyl)lysine and sRAGE levels are inversely associated with a number of metabolic syndrome risk factors in non-diabetic young-to-middle-aged medication-free subjects. Clinical Chemistry and Laboratory Medicine, 2014, 52, 139-49.	2.3	39
46	Comprehensive assessment of nephrotoxicity of intravenously administered sodium-oleate-coated ultra-small superparamagnetic iron oxide (USPIO) and titanium dioxide (TiO₂) nanoparticles in rats. Nanotoxicology, 2014, 8, 142-157.	3.0	23
47	A pilot study of a genetic CJD risk factor (E200K) in the general Slovak population. European Journal of Epidemiology, 2014, 29, 595-597.	5.7	8
48	Can metabolic impairments in experimental diabetes be cured with poly(amido)amine (PAMAM) G4 dendrimers? â€“ In the search for minimizing of the adverse effects of PAMAM administration. International Journal of Pharmaceutics, 2014, 464, 152-167.	5.2	21
49	26. Advanced glycation end products in infant formulas. Human Health Handbooks, 2014, , 421-440.	0.1	4
50	Sex differences of oxidative stress markers in young healthy subjects are marker-specific in plasma but not in saliva. Annals of Human Biology, 2013, 40, 175-180.	1.0	15
51	Advanced Glycation End Products in Infant Formulas Do Not Contribute to Insulin Resistance Associated with Their Consumption. PLoS ONE, 2013, 8, e53056.	2.5	28
52	Neuronal Activation in the Central Nervous System of Rats in the Initial Stage of Chronic Kidney Disease-Modulatory Effects of Losartan and Moxonidine. PLoS ONE, 2013, 8, e66543.	2.5	16
53	The Effects of Anti-Inflammatory and Anti-Angiogenic DNA Vaccination on Diabetic Nephropathy in Rats. Human Gene Therapy, 2012, 23, 158-166.	2.7	11
54	Advanced Oxidation Protein Products and Advanced Glycation End Products in Children and Adolescents With Chronic Renal Insufficiency. , 2012, 22, 143-148.		29

#	Article	IF	Citations
55	Neuromuscular electrostimulation techniques: historical aspects and current possibilities in treatment of pain and muscle waisting. Clinical Nephrology, 2012, , .	0.7	32
56	Advanced glycation end products in myocardial reperfusion injury. Heart and Vessels, 2012, 27, 208-215.	1.2	8
57	Behaviour and hormonal status in healthy rats on a diet rich in Maillard reaction products with or without solvent extractable aroma compounds. Physiology and Behavior, 2012, 105, 693-701.	2.1	26
58	Association of sVAP-1, sRAGE, and CML with lactation-induced insulin sensitivity in young non-diabetic healthy women. Clinica Chimica Acta, 2011, 412, 1842-1847.	1.1	3
59	AT1 Receptor Antagonist Candesartan Attenuates Genomic Damage in Peripheral Blood Lymphocytes of Patients on Maintenance Hemodialysis Treatment. Kidney and Blood Pressure Research, 2011, 34, 167-172.	2.0	8
60	The peroxisome proliferator-activated receptor-Î± agonist, BAY PP1, attenuates renal fibrosis in rats. Kidney International, 2011, 80, 1182-1197.	5.2	45
61	Karl Peterâ€™s fundamental contribution to the structural organization of the kidney. Journal of Nephrology, 2011, 24, 51-57.	2.0	1
62	Metabolic syndrome is inversely related to soluble receptor for advanced glycation end products: a study in mother-infant pairs. Biopolymers and Cell, 2011, 27, 132-140.	0.4	0
63	Renal and metabolic effects of three months of decarbonated cola beverages in rats. Experimental Biology and Medicine, 2010, 235, 1321-1327.	2.4	11
64	Advanced Glycation End Products and Acute Myocardial Infarction. Medical Principles and Practice, 2010, 19, 244-246.	2.4	2
65	Mechanisms of Acute Uremic Encephalopathy: Early Activation of Fos and Fra-2 Gene Products in Different Nuclei/Areas of theÂRat Brain. , 2010, 20, S44-S50.		10
66	Association of biochemical parameters and RAGE gene polymorphisms in healthy infants and their mothers. Clinica Chimica Acta, 2010, 411, 1034-1040.	1.1	12
67	Oxidative stress, advanced glycation end products and residual renal function in the rat model of unilateral ureteral obstruction: effects of phlogenzym and losartan. Biopolymers and Cell, 2010, 26, 121-127.	0.4	1
68	Functional and Partial Morphological Regression of Established Renal Injury in the Obese Zucker Rat by Blockade of the Renin-Angiotensin System. American Journal of Nephrology, 2009, 29, 164-170.	3.1	15
69	Testing strategies for the safety of nanoparticles used in medical applications. Nanomedicine, 2009, 4, 605-607.	3.3	57
70	Plasma advanced glycation end products are decreased in obese children compared with lean controls. Pediatric Obesity, 2009, 4, 112-118.	3.2	67
71	Renal, vascular and cardiac fibrosis in rats exposed to passive smoking and industrial dust fibre amosite. Journal of Cellular and Molecular Medicine, 2009, 13, 4484-4491.	3.6	39
72	Neuronal activation in the CNS during different forms of acute renal failure in rats. Neuroscience, 2009, 159, 862-882.	2.3	32

#	Article	IF	Citations
73	Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism: Clinical and Experimental, 2009, 58, 1669-1677.	3.4	99
74	Development of methodology for alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics. NanoTEST â€“ EC FP7 project. Journal of Physics: Conference Series, 2009, 170, 012039.	0.4	3
75	PAMAM G4 dendrimers lower high glucose but do not improve reduced survival in diabetic rats. International Journal of Pharmaceutics, 2008, 364, 142-149.	5.2	31
76	Plasma Concentration and Urinary Excretion of N^Éâ€(Carboxymethyl)lysine in Breast Milkâ€“ and Formulaâ€fed Infants. Annals of the New York Academy of Sciences, 2008, 1126, 177-180.	3.8	73
77	The Selective TP Receptor Antagonist, S18886 (Terutroban), Attenuates Renal Damage in the Double Transgenic Rat Model of Hypertension. American Journal of Nephrology, 2008, 28, 47-53.	3.1	17
78	Les produits de Maillard issus de la cuisson ont-ils des effets biologiques ?. Sciences Des Aliments, 2008, 28, 223-230.	0.2	4
79	Treatment targets in renal fibrosis. Nephrology Dialysis Transplantation, 2007, 22, 3391-3407.	0.7	132
80	Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney International, 2007, 72, 1113-1121.	5.2	74
81	Renal Effects of S18886 (Terutroban), a TP Receptor Antagonist, in an Experimental Model of Type 2 Diabetes. Diabetes, 2007, 56, 968-974.	0.6	37
82	Genomic Damage and Malignancy in End-Stage Renal Failure: Do Advanced Glycation End Products Contribute?. Kidney and Blood Pressure Research, 2007, 30, 56-66.	2.0	11
83	Dietary advanced glycation endproducts (AGEs) and their health effects â€“ PRO. Molecular Nutrition and Food Research, 2007, 51, 1079-1084.	3.3	136
84	Renal Disease in Obesity: The Need for Greater Attention. , 2006, 16, 216-223.		87
85	Association of metabolic syndrome risk factors with selected markers of oxidative status and microinflammation in healthy omnivores and vegetarians. Molecular Nutrition and Food Research, 2006, 50, 858-868.	3.3	57
86	Relation between Different Treatment Modalities and Genomic Damage of End-Stage Renal Failure Patients. Kidney and Blood Pressure Research, 2006, 29, 10-17.	2.0	25
87	Rooibos tea (Aspalathus linearis) partially prevents oxidative stress in streptozotocin-induced diabetic rats. Physiological Research, 2006, 55, 157-64.	0.9	39
88	Renal Effects of Oral Maillard Reaction Product Load in the Form of Bread Crusts in Healthy and Subtotally Nephrectomized Rats. Annals of the New York Academy of Sciences, 2005, 1043, 482-491.	3.8	43
89	Dietary Bread Crust Advanced Glycation End Products Bind to the Receptor for AGEs in HEK-293 Kidney Cells but Are Rapidly Excreted after Oral Administration to Healthy and Subtotally Nephrectomized Rats. Annals of the New York Academy of Sciences, 2005, 1043, 492-500.	3.8	36
90	Increased Protein Glycation in Cirrhosis and Therapeutic Strategies to Prevent It. Annals of the New York Academy of Sciences, 2005, 1043, 718-724.	3.8	25

#	Article	IF	Citations
91	Reduced Circulating AGE Levels and Lower Genomic Damage in Patients Undergoing Daily versus Standard Hemodialysis. Annals of the New York Academy of Sciences, 2005, 1043, 925-925.	3.8	1
92	Tissue viral DNA is associated with chronic allograft nephropathy. Pediatric Transplantation, 2005, 9, 598-603.	1.0	12
93	Genetic variability in the RAGE gene: Possible implications for nutrigenetics, nutrigenomics, and understanding the susceptibility to diabetic complications. Molecular Nutrition and Food Research, 2005, 49, 700-709.	3.3	15
94	Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis. Nephrology Dialysis Transplantation, 2005, 20, 1936-1943.	0.7	46
95	Genomic damage in chronic renal failureâ€"potential therapeutic interventions. , 2005, 15, 81-86.		20
96	Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation. Heart, 2004, 90, 1269-1274.	2.9	14
97	Serum Growth Factors in Hemodialyzed Patients. Artificial Organs, 2004, 28, 314-316.	1.9	5
98	Genomic damage in end-stage renal failure: Potential involvement of advanced glycation end products and carbonyl stress. Seminars in Nephrology, 2004, 24, 474-478.	1.6	22
99	Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. Journal of Hepatology, 2004, 41, 913-919.	3.7	59
100	Effects of a diet rich in advanced glycation end products in the rat remnant kidney model. American Journal of Kidney Diseases, 2003, 41, S48-S51.	1.9	46
101	Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. Journal of Human Hypertension, 2003, 17, 265-270.	2.2	62
102	Genotoxicity of advanced glycation end products in mammalian cells. Cancer Letters, 2003, 190, 151-156.	7.2	107
103	Functional Hyperhomocysteinemia in Healthy Vegetarians: No Association with Advanced Glycation End Products, Markers of Protein Oxidation, or Lipid Peroxidation after Correction with Vitamin B12. Clinical Chemistry, 2003, 49, 983-986.	3.2	9
104	Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis â€" amelioration by liver transplantation. Journal of Hepatology, 2002, 36, 66-71.	3.7	109
105	Advanced glykation end products in patients with liver cirrhosis before and after liver transplantation. Journal of Hepatology, 2002, 36, 58.	3.7	0
106	Effects of dietary NÎµ-carboxymethyllysine on expression of the biotransformation enzyme, glutathione-S-transferase, in the rat. International Congress Series, 2002, 1245, 313-320.	0.2	7
107	Does magnesium dysbalance participate in the development of insulin resistance in early stages of renal disease?. Physiological Research, 2002, 51, 605-12.	0.9	3
108	Advanced Glycation End Products in End-Stage Renal Disease and Their Removal. Nephron, 2001, 87, 295-303.	1.8	50

#	Article	IF	Citations
109	Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet. European Journal of Nutrition, 2001, 40, 275-281.	3.9	77
110	Advanced glycation end products impair protein turnover in LLC-PK1: Amelioration by trypsin. Kidney International, 2001, 59, S53-S57.	5.2	10
111	Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure. Kidney International, 2001, 59, S58-S62.	5.2	24
112	DNA damage of lymphocytes in experimental chronic renal failure: Beneficial effects of losartan. Kidney International, 2001, 59, S212-S215.	5.2	7
113	Plasma levels of advanced glycation end products in children with renal disease. Pediatric Nephrology, 2001, 16, 1105-1112.	1.7	41
114	Franz Volhard and Theodor Fahr: achievements and controversies in their research in renal disease and hypertension. Journal of Human Hypertension, 2001, 15, 5-16.	2.2	24
115	Advanced glycation end products and the progressive course of renal disease. American Journal of Kidney Diseases, 2001, 38, S100-S106.	1.9	138
116	Advanced glycation end products (AGEs)â€induced expression of TGFâ€Î²1 is suppressed by a protease in the tubule cell line LLCâ€PK1. Nephrology Dialysis Transplantation, 2001, 16, 1562-1569.	0.7	25
117	DNA damage of lymphocytes in experimental chronic renal failure: Beneficial effects of losartan. Kidney International, 2001, 59, 212-215.	5.2	5
118	Advanced glycation end products impair protein turnover in LLC-PK1: Amelioration by trypsin. Kidney International, 2001, 59, 53-57.	5.2	6
119	Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure. Kidney International, 2001, 59, 58-62.	5.2	0
120	Evidence for Accumulation of Advanced Glycation End Products in Acute Renal Failure. Nephron, 2000, 86, 186-187.	1.8	4
121	Enalapril Inhibits Growth and Proliferation of Various Tissues in Rat Normotensive Fourâ€“Sixths Kidney Ablation Nephropathy. Kidney and Blood Pressure Research, 2000, 23, 106-112.	2.0	1
122	The effect of oral protease administration in the rat remnant kidney model. Research in Experimental Medicine, 1999, 199, 177-188.	0.7	5
123	Suppressed Activities of Cathepsins and Metalloproteinases in the Chronic Model of Puromycin Aminonucleoside Nephrosis. Kidney and Blood Pressure Research, 1999, 22, 121-127.	2.0	12
124	Advanced Glycation End-Product Levels in Subtotally Nephrectomized Rats: Beneficial Effects of Angiotensin II Receptor 1 Antagonist Losartan. Mineral and Electrolyte Metabolism, 1999, 25, 380-383.	1.1	37
125	Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat. Physiological Research, 1999, 48, 429-35.	0.9	4
126	Mesangial cell hypertrophy induced by NH4Cl: Role of depressed activities of cathepsins due to elevated lysosomal pH. Kidney International, 1998, 53, 1706-1712.	5.2	34

#	Article	IF	Citations
127	Effective long-term inhibition of thromboxane production but not of serotonin release in patients with coronary heart disease by 30 mg/d acetylsalicylic acid dosage. Prostaglandins Leukotrienes and Essential Fatty Acids, 1998, 59, 17-21.	2.2	4
128	Effect of Chronic Therapy with Proteolytic Enzymes on Hypertension-Induced Renal Injury in the Rat Model of Goldblatt Hypertension. American Journal of Nephrology, 1998, 18, 570-576.	3.1	17
129	High-Glucose Media Enhance the Responsiveness of Tubular Cells to Growth Promoters: Effect on Lysosomal Cathepsins and Protein Degradation. Mineral and Electrolyte Metabolism, 1998, 24, 254-260.	1.1	17
130	Advanced glycated albumin impairs protein degradation in the kidney proximal tubules cell line LLC-PK1. Cellular and Molecular Biology, 1998, 44, 1051-60.	0.9	32
131	Effects of protease therapy in the remnant kidney model of progressive renal failure. Mineral and Electrolyte Metabolism, 1997, 23, 291-5.	1.1	4
132	Inhibition of glucose uptake by 5-hydroxyindoleacetic acid in the isolated rat soleus muscle. International Urology and Nephrology, 1996, 28, 123-131.	1.4	4
133	Plasma Levels of 5-Hydroxyindole-Acetic Acid in Chronic Renal Insufficiency and Their Effect on Platelet Aggregation. Nephron, 1991, 58, 253-254.	1.8	3
134	Serotonin and Platelet Activation During Treatment with Isradipine. Journal of Cardiovascular Pharmacology, 1991, 18, S31-S33.	1.9	3
135	Serotonin Metabolism in Patients with Decreased Renal Function. Nephron, 1989, 53, 229-232.	1.8	20
136	Perturbation of baseline in HPLC analysis as the consequence of sample injection. Journal of High Resolution Chromatography, 1988, 11, 598-600.	1.4	2
137	Serotonin Metabolism and Platelet Aggregation Under Antihypertensive Treatment with Nitrendipine. Journal of Cardiovascular Pharmacology, 1988, 12, S161-S163.	1.9	3
138	Dependence of the separation of some biological substances on the carbon content of C18 chemically bonded phases. Journal of Chromatography A, 1986, 367, 171-180.	3.7	12
139	Evaluation of various bonded-phase materials for the off-line clean-up procedure of urinary 5-hydroxyindolacetic acid prior to its determination by HPLC. Chromatographia, 1986, 22, 299-302.	1.3	12
140	Fibroblast growth factor-21 (FGF-21) - marker of mineral bone disorder. Bone Abstracts, 0, , .	0.0	0
141	AGEs Fluorescence of Plasma, Urine and Skin Reflects Dietary Exposure to Maillard Products in Formula-fed Infants. , 0, , 180-187.		1
142	The Effect of Long-Term Hypogonadism on Body Composition and Morphometry of Aged Male Wistar Rats. Physiological Research, 0, , S357-S367.	0.9	3